FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation

Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood…

Read MoreFDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation